Cancer News and Research

Latest Cancer News and Research

Solid-dominant lung cancer histology no barrier to segmentectomy

Complete resection with segmentectomy is as effective as lobectomy for patients with solid-dominant clinical stage IA lung adenocarcinoma, Japanese study findings suggest.

31 Mar 2014

Lobar offers no survival advantage over sublobar resections in NSCLC

Patients do not survive significantly longer after lobectomy for non-small-cell lung cancer than after wedge resection or segmentectomy, indicate US study results.

31 Mar 2014

Americans' experience with health law depends on where they live

Some states that embraced the law, like Oregon, have had difficulty enrolling residents because of glitch-ridden online marketplaces, while others like New Hampshire have seen unexpectedly strong enrollments despite prevailing critical views.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

First Edition: March 31, 2014

Today's early morning highlights from the major news organizations offer assessments of the administration's campaign to get people signed up for health care and a look at the issues going forward after today's deadline for most enrollments.

31 Mar 2014

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.

31 Mar 2014

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.

31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014

International scientists identify novel genetic defects that induce oesophageal cancer

A team of scientists from the Cancer Science Institute of Singapore at the National University of Singapore and National University Cancer Institute Singapore, and their collaborators from the Cedars-Sinai Medical Centre, UCLA School of Medicine, demonstrated that a number of novel genetic defects are able to induce oesophageal cancer.

31 Mar 2014

New gene-editing system holds potential for treating many genetic disorders

Using a new gene-editing system based on bacterial proteins, MIT researchers have cured mice of a rare liver disorder caused by a single genetic mutation.

31 Mar 2014

Studies reveal role of spiritual care in treating people facing serious illnesses

Two of six studies released today, reveal important advances in understanding the role of spiritual care in treating people facing serious illness, including cancer and ALS. Until now, no empirical data has existed on the contributions of chaplains in health care.

31 Mar 2014

New high-risk cancer causing mutation identified for melanoma development

Researchers have discovered that mutations in a specific gene are responsible for a hereditary form of melanoma.

31 Mar 2014

Einstein faculty members present recent research at AACR Annual Meeting

From uncovering the role nerve cells play in metastasis to identifying new cancer-causing genes, researchers at Albert Einstein College of Medicine of Yeshiva University made notable advances in the understanding and potential treatment of cancer during the past year.

29 Mar 2014

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.

29 Mar 2014

Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Centralization of specialized health care services such as organ transplantation and bariatric surgery is advocated to improve quality, increase efficiency, and reduce cost.

29 Mar 2014

Cancer News and Research

Latest Cancer News and Research

Solid-dominant lung cancer histology no barrier to segmentectomy

Lobar offers no survival advantage over sublobar resections in NSCLC

Americans' experience with health law depends on where they live

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

First Edition: March 31, 2014

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

International scientists identify novel genetic defects that induce oesophageal cancer

New gene-editing system holds potential for treating many genetic disorders

Studies reveal role of spiritual care in treating people facing serious illnesses

New high-risk cancer causing mutation identified for melanoma development

Einstein faculty members present recent research at AACR Annual Meeting

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Newsletters you may be interested in